G&E Herbal Biotechnology Co., Ltd. (4911) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of G&E Herbal Biotechnology Co., Ltd. stock TWD 37.16, price TWD 25.00, upside +48.6%, quality 77 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 17.35 TWD – 339.40 TWD · fair‑value band 13.75 TWD – 48.17 TWD · the 25.00 TWD price screens below the 37.16 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow G&E Herbal Biotechnology Co. in your weekly email
Every Wednesday you see whether G&E Herbal Biotechnology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
G&E Herbal Biotechnology Co., Ltd. engages in manufacturing and wholesale of western and chinese medicine, cosmetics, intellectual property rights, biotechnology services, medical device, and other unclassified food products in Taiwan.
Show moreShow less
It offers HepaGent capsules, a liver protective agent; botanical food supplements; botanical anti-aging cosmetics, such as facial cleansing essence, botanic extract toner, moisturizing cream and serum, and essential oil; smile cream and topical gel; as well as lubricants.
G&E Herbal Biotechnology Co., Ltd. was founded in 2002 and is based in Tainan City, Taiwan.
Stock analysis
G&E Herbal Biotechnology Co., Ltd. (4911) currently trades at 25.00 TWD, while our model-based Fair Value estimate is 37.16 TWD, implying the stock looks roughly 33% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 93.98 TWD per share, and 12 of the 26 models we run sit above the 25.00 TWD price.
Bear case: the Asset-Based group reads lowest at 6.21 TWD, and 14 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 13.75 TWD (bear) to 48.17 TWD (bull), the price of 25.00 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 77/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
G&E Herbal Biotechnology Co., Ltd. reported revenue of 309M TWD in FY2025 versus 24.6M TWD in FY2021, a compound +88.3%/yr. Reported net income was 139M TWD in FY2025.
Key figures
Market cap 1.8B TWD (≈ $53.4M) Micro · P/E ratio 20.5 · P/S ratio 8.13 · EPS (TTM) 1.22 TWD · Dividend yield 4.3% · Net margin 40.0% · Return on equity 9.9% · Return on assets (EBIT) 7.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 73 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 49%, 4911 screens cheaper than that median.
Fair Value models
Bear13.75 TWDFair Value 37.16 TWDBull48.17 TWD
Price 25.00 TWD · Upside +48.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.1201 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.86/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+24.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+68.5%
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in TWD (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+98.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+93.7%
Dividend (yield on the price)4.3%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−80% → 49%
2025 sits 92% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +18.5% a year for the price.
Compare G&E Herbal Biotechnology Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score77 · Top 25%
Fair Value upside+48.6% · Top 25%
Profitability
Return on equity (12 months)9.9% · Top 25%
Return on assets14.3% · Top 25%
Net margin (12 months)40.0% · Top 25%
Operating margin (12 months)23.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−57.0% · Bottom 25%
Dividend yield (12 months)4.3% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)20.5× · Cheaper than median
P/B1.89× · Cheaper than median
P/S (12 months)8.13× · Pricier than median
Price / free cash flow (fiscal year)26.2× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is G&E Herbal Biotechnology Co., Ltd. (4911) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 37.16 TWD versus a price of 25.00 TWD, about +49% upside (undervalued).
What is the fair value of 4911?
Our model-based fair value for G&E Herbal Biotechnology Co., Ltd. is 37.16 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 25.00 TWD.
What is the quality score of 4911?
G&E Herbal Biotechnology Co., Ltd. has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for G&E Herbal Biotechnology Co., Ltd. (4911)?
Our model-based price target is the fair value of 37.16 TWD (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 13.75 TWD, optimistic scenario 48.17 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the G&E Herbal Biotechnology Co., Ltd. stock forecast for 2026?
Our models put fair value at 37.16 TWD, about +49% upside versus a price of 25.00 TWD (undervalued). Cautious scenario 13.75 TWD, optimistic scenario 48.17 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of G&E Herbal Biotechnology Co., Ltd. (4911)?
G&E Herbal Biotechnology Co., Ltd. reported trailing-twelve-month revenue of about 216M TWD (latest available figure, as of Nov 9, 2026).
Does G&E Herbal Biotechnology Co., Ltd. pay a dividend?
G&E Herbal Biotechnology Co., Ltd. currently shows a dividend yield of 4.32% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of G&E Herbal Biotechnology Co., Ltd. (4911) and when is the ex-dividend date?
G&E Herbal Biotechnology Co., Ltd. pays a dividend of 1.08 TWD per share a year, a dividend yield of 4.3%. The last ex-dividend date was Jul 28, 2026. The payout ratio is 88.5% of earnings. Free cash flow covers the dividend 0.90 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into G&E Herbal Biotechnology Co., Ltd. (4911)?
For today's price to be fair in a discounted-cash-flow model, G&E Herbal Biotechnology Co., Ltd. would have to grow free cash flow by +20.3 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +88.3 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 4911 use?
Our models discount G&E Herbal Biotechnology Co., Ltd. at 13.3 %: a base by market capitalisation (micro), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For G&E Herbal Biotechnology Co., Ltd. that is +20.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has G&E Herbal Biotechnology Co., Ltd. (4911) delivered so far?
Over the past 4 years revenue at G&E Herbal Biotechnology Co., Ltd. grew +88.3 % a year. The price currently implies free-cash-flow growth of +20.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of G&E Herbal Biotechnology Co., Ltd. (4911) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into G&E Herbal Biotechnology Co., Ltd. (+20.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of G&E Herbal Biotechnology Co., Ltd. (4911)?
The free-cash-flow yield on the price is 4.20 %: that much free cash flow G&E Herbal Biotechnology Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of G&E Herbal Biotechnology Co., Ltd. (4911)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For G&E Herbal Biotechnology Co., Ltd. it is 37.16 TWD per share (as of Nov 9, 2026), against a price of 25.00 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is G&E Herbal Biotechnology Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 4911 trades below its calculated fair value: price 25.00 TWD, fair value 37.16 TWD, a gap of about +49% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4911?
No. The price is what the market pays today (25.00 TWD); the fair value is what the company's own numbers justify (37.16 TWD). For G&E Herbal Biotechnology Co., Ltd. the two are 12.16 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is G&E Herbal Biotechnology Co., Ltd. worth?
The market values G&E Herbal Biotechnology Co., Ltd. at about 1.8B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 25.00 TWD; our models calculate a fair value of 37.16 TWD per share.
What do the bullish and bearish scenarios say about 4911?
Our models span a range for G&E Herbal Biotechnology Co., Ltd.: cautious scenario 13.75 TWD, base 37.16 TWD, optimistic 48.17 TWD per share (as of Nov 9, 2026, price 25.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4911?
G&E Herbal Biotechnology Co., Ltd. trades at a price-to-earnings ratio of 20.5 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 37.16 TWD is built from several models across several years. Other multiples: P/B 1.9, P/S 8.1, EV/EBITDA 18.1.
How solid is the balance sheet of G&E Herbal Biotechnology Co., Ltd. (4911)?
Balance-sheet figures for G&E Herbal Biotechnology Co., Ltd. (as of Nov 9, 2026): return on equity 9.9%. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is 4911 from its 52-week high?
G&E Herbal Biotechnology Co., Ltd. trades at 25.00 TWD, about 43% below its 52-week high of 43.74 TWD and at the low of 25.00 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 37.16 TWD is for.
Which stocks are comparable to G&E Herbal Biotechnology Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is G&E Herbal Biotechnology Co., Ltd. stock attractive at the current price?
The data as of Nov 9, 2026: price 25.00 TWD, calculated fair value 37.16 TWD (+49%), Quality Score 77/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4911 calculated?
We run G&E Herbal Biotechnology Co., Ltd. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 37.16 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. G&E Herbal Biotechnology Co., Ltd. currently trades 33% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of G&E Herbal Biotechnology Co., Ltd. (4911)?
The closing price on Nov 6, 2026 was 25.00 TWD. Our model-based fair value is 37.16 TWD, about +49% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with G&E Herbal Biotechnology Co., Ltd. right now?
The rarer combination: high quality (77/100) AND below fair value. That earns a closer look rather than a quick verdict. The model range is unusually wide (13.75 TWD to 48.17 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of G&E Herbal Biotechnology Co., Ltd.
How large is the market capitalisation of G&E Herbal Biotechnology Co., Ltd. (4911)?
The market capitalisation of G&E Herbal Biotechnology Co., Ltd. is 1.8B TWD (≈ $53.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of G&E Herbal Biotechnology Co., Ltd. (4911)?
The price-to-sales ratio of G&E Herbal Biotechnology Co., Ltd. is 8.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of G&E Herbal Biotechnology Co., Ltd. (4911)?
Earnings per share at G&E Herbal Biotechnology Co., Ltd. are 1.22 TWD (price ÷ EPS = P/E 20.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of G&E Herbal Biotechnology Co., Ltd. (4911)?
The dividend yield of G&E Herbal Biotechnology Co., Ltd. is 4.3% (payout 88.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of G&E Herbal Biotechnology Co., Ltd. (4911)?
The net margin of G&E Herbal Biotechnology Co., Ltd. is 40.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of G&E Herbal Biotechnology Co., Ltd. (4911)?
The return on equity (ROE) of G&E Herbal Biotechnology Co., Ltd. is 9.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of G&E Herbal Biotechnology Co., Ltd. (4911)?
On an EBIT basis the return on assets of G&E Herbal Biotechnology Co., Ltd. is 7.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of G&E Herbal Biotechnology Co., Ltd. (4911)?
The operating margin of G&E Herbal Biotechnology Co., Ltd. is 23.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at G&E Herbal Biotechnology Co., Ltd. (4911)?
Revenue at G&E Herbal Biotechnology Co., Ltd. is growing −57.0% versus a year earlier (3y avg +68.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at G&E Herbal Biotechnology Co., Ltd. (4911)?
Earnings per share at G&E Herbal Biotechnology Co., Ltd. are growing −80.7% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch G&E Herbal Biotechnology Co., Ltd. in the live analysis
One click puts G&E Herbal Biotechnology Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026